Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Netarsudil mesylate - Aerie Pharmaceuticals

Drug Profile

Netarsudil mesylate - Aerie Pharmaceuticals

Alternative Names: AR-13224; AR13324; Netarsudil mesylate; Netarsudil ophthalmic solution - Aerie Pharmaceuticals; Rhokiinsa; Rhopressa

Latest Information Update: 29 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duke University Medical Center
  • Developer Aerie Pharmaceuticals; Cornea Research Foundation of America
  • Class Antiglaucomas; Eye disorder therapies; Isoquinolines; Small molecules
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Ocular hypertension; Open-angle glaucoma
  • No development reported Neurological disorders

Most Recent Events

  • 21 Nov 2019 Registered for Ocular hypertension in Norway, Liechtenstein, Iceland, European Union (Ophthalmic)
  • 21 Nov 2019 Registered for Open-angle glaucoma in Norway, Liechtenstein, Iceland, European Union (Ophthalmic)
  • 06 Nov 2019 Netarsudil mesylate - Aerie Pharmaceuticals is available for licensing in Japan as of 06 Nov 2019. https://aeriepharma.com/ 9279017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top